Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int Immunopharmacol
Main Authors: Malekzadeh, Reza, Abedini, Atefeh, Mohsenpour, Behzad, Sharifipour, Ehsan, Ghasemian, Roya, Javad-Mousavi, Seyed Ali, Khodashahi, Rozita, Darban, Mahboobeh, Kalantari, Saeed, Abdollahi, Nafiseh, Salehi, Mohammad Reza, Rezaei Hosseinabadi, Abbas, Khorvash, Farzin, Valizadeh, Melika, Dastan, Farzaneh, Yousefian, Sahar, Hosseini, Hamed, Anjidani, Nassim, Tabarsi, Payam
Formato: Artigo
Idioma:Inglês
Publicado em: Published by Elsevier B.V. 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7553010/
https://ncbi.nlm.nih.gov/pubmed/33075713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.107102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados